A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.

BMC Endocr Disord · 2014 · PMC3946011 · PMID 24565221

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the current study, reductions in placebo-adjusted FPG, though of similar magnitude with the statistically significant reductions in FPG with saxagliptin add-on therapy in other studies, did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.